BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/23/2021 2:14:14 PM | Browse: 674 | Download: 2536
 |
Received |
|
2021-04-22 20:53 |
|
Peer-Review Started |
|
2021-04-22 20:56 |
|
First Decision by Editorial Office Director |
|
2021-05-24 01:19 |
|
Return for Revision |
|
2021-05-24 01:19 |
|
Revised |
|
2021-06-04 19:17 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-07-02 13:05 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-07-02 13:39 |
|
Articles in Press |
|
2021-07-02 13:39 |
|
Edit the Manuscript by Language Editor |
|
2021-11-17 16:02 |
|
Typeset the Manuscript |
|
2021-12-07 02:26 |
|
Publish the Manuscript Online |
|
2021-12-23 14:14 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jose María Huguet, Xavier Cortés, Marta Maia Bosca-Watts, Marian Aguas, Nuria Maroto, Lidia Martí, Cirilo Amorós and Jose María Paredes |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jose María Huguet, MD, Reader (Associate Professor), Department of Gastroenterology, General University Hospital of Valencia, Av Tres cruces, Valencia 46014, Spain. josemahuguet@gmail.com |
| Key Words |
Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease; Infliximab; Biosimilar; CT-P13 |
| Core Tip |
In this work, we have analyzed the effectiveness and safety of the infliximab biosimilar CT-P13 in the treatment of inflammatory bowel disease (IBD) in real-life practice. Our results show that CT-P13 is an effective and safe biosimilar of infliximab, being a valid and attractive alternative for the treatment of IBD since it allows for a reduction of healthcare costs and facilitates access to biological treatments for more patients. |
| Publish Date |
2021-12-23 14:14 |
| Citation |
Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i36/11285.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i36.11285 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
